Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology Corporation (Nasdaq: PDSB) announced Matthew Hill as the new Chief Financial Officer, effective October 18, 2021. Hill, with over 25 years of experience in finance within life sciences, previously held the CFO role at Strata Skin Sciences. He aims to guide PDS Biotech's financial strategy in a critical growth phase, especially with its proprietary Versamune® technology for cancer therapies. The company acknowledges the contribution of outgoing CFO Seth Van Voorhees. PDS Biotech focuses on developing innovative cancer treatments targeting several cancer types.

PDS Biotechnology Corporation (Nasdaq: PDSB) has completed enrollment for the first stage of the checkpoint inhibitor naïve arm in its VERSATILE-002 Phase 2 study targeting recurrent HPV16-associated head and neck cancer. This ambitious trial aims to assess the efficacy of PDS0101, in collaboration with Merck & Co. A significant milestone was achieved as objective response will be evaluated based on tumor reduction. If four out of the first 17 patients show positive results, the study will progress to the second stage involving 54 additional patients.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. The company will update on three ongoing PDS0101 Phase 2 clinical trials and progress on PDS0102 and PDS0103 into human clinical trials. CEO Dr. Frank Bedu-Addo will also join an oncology panel discussion. The company’s innovative Versamune^® technology aims to enhance T-cell responses against various cancers. Investors can register online for the event and access a webcast replay post-conference.

PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The presentation on September 28 at 4:40 PM EDT will cover updates on three ongoing Phase 2 clinical trials for PDS0101, along with advancements for investigational products PDS0102 and PDS0103. Following the conference, a replay will be available on the company's website. PDS Biotech focuses on cancer therapies utilizing its Versamune^® T-cell activating technology.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced that its VERSATILE-002 Phase 2 study for treating advanced HPV16-associated head and neck cancer reached a preliminary safety benchmark. No dose-limiting toxicities were observed in the initial 12 patients. The trial will continue enrollment for efficacy evaluation among 17 checkpoint inhibitor (CPI) naïve patients and 21 CPI refractory patients. The study aims to advance based on tumor response criteria. PDS0101, in combination with KEYTRUDA, targets an unmet medical need in advanced cancer treatment.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced an equity award to Gregory Reid, its new VP of Program Development, as an inducement for joining the company. This award includes 63,800 shares with an exercise price of $14.99, vesting over four years. Reid brings over 30 years of pharmaceutical industry experience, particularly in oncology product development. His expertise aims to advance PDS Biotech's innovative cancer immunotherapy pipeline, leveraging its proprietary Versamune® technology, which targets various cancers effectively.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101 and developments of PDS0102 and PDS0103 in human clinical trials. The presentation is scheduled for September 21, 2021, at 3:45 PM EDT. A webcast will follow on the company's investor website. PDSB focuses on innovative cancer therapies utilizing its proprietary Versamune^® T-cell activating technology.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the completion of enrollment in the lead-in safety cohort for its VERSATILE-002 Phase 2 study. This trial evaluates the efficacy and safety of the combination of PDS0101 and KEYTRUDA^® for treating HPV16-associated head and neck cancer. The study includes approximately 100 patients across 25 centers in the U.S. Preliminary data shows promising responses, with 83% of CPI naïve patients showing tumor reduction. The company aims to address the significant unmet medical needs in advanced HPV-related cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the HC Wainwright 23rd Annual Global Investment Conference, set for September 13-15, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101, along with progress on PDS0102 and PDS0103, which are entering human clinical trials. The presentation will be available on demand starting September 13 at 7:00 am EDT on the company’s website. PDS Biotech specializes in immunotherapy based on its Versamune^® technology, targeting various cancers including breast and lung cancer.